神经痛的特征是由体感系统的损伤或疾病引起的慢性疼痛,包括负责传递感觉信息的神经.目前神经性疼痛的治疗方法,这是一种神经痛,成功率有限,并可能导致不必要的副作用。自1989年以来,肉毒杆菌毒素A(BTX-A),来自强效的神经毒素肉毒梭状芽孢杆菌,已被用于治疗人类的神经性疼痛。BTX-A通过抑制参与疼痛传递的神经递质的释放而显示出镇痛作用。本综述旨在评估BTX-A在各种类型神经痛中的有效性。指导本综述的研究问题是BTX-A在减轻不同类型神经疼痛方面是否安全有效。为了进行这次审查,使用PubMed进行了文献检索,Medline,和PubMedCentral数据库。搜索策略包括与BTX-A相关的相关关键词,神经痛,和神经性疼痛。筛选标题后,摘要,和全文,共有30篇文章被纳入审查。这些研究检查了BTX-A在各种情况下的疗效,例如带状疱疹后遗神经痛(PHN),耳颞部神经痛(ATN),枕骨神经痛(ON),麻风病引起的神经性疼痛(LIN),局灶性疼痛性神经病,复杂区域疼痛综合征(CRPS),三叉神经痛(TN),与脊髓损伤相关的神经性疼痛。然而,需要进一步的研究来增强我们对BTX-A在特定神经痛中的最佳使用的理解.重要的是要承认纳入研究的局限性。然而,BTX-A可能被认为是神经痛的可行治疗选择。
Neuralgia is characterized by chronic pain resulting from damage or diseases in the somatosensory system, including nerves responsible for transmitting sensory information. Current treatments for neuropathic pain, which is a type of neuralgia, have limited success rates and can cause unwanted side effects. Since 1989, botulinum toxin-A (BTX-A), derived from the potent neurotoxin Clostridium botulinum, has been used to treat neuropathic pain in humans. BTX-A has shown analgesic effects by inhibiting the release of neurotransmitters involved in pain transmission. This
review aims to evaluate the effectiveness of BTX-A in various types of neuralgia. The research question guiding this
review is whether BTX-A is safe and effective in reducing pain in different types of neuralgias. To conduct this
review, a literature search was performed using the PubMed, Medline, and PubMed Central databases. The search strategy included relevant keywords related to BTX-A, neuralgia, and neuropathic pain. After screening titles, abstracts, and full texts, a total of 30 articles were included in the
review. These studies examined the efficacy of BTX-A in various conditions such as postherpetic neuralgia (PHN), auriculotemporal neuralgia (ATN), occipital neuralgia (ON), leprosy-induced neuropathic pain (LIN), focal painful neuropathies, complex regional pain syndrome (CRPS), trigeminal neuralgia (TN), and neuropathic pain associated with spinal cord injury. However, further research is needed to enhance our understanding of the optimal use of BTX-A in specific neuralgias. It is important to acknowledge the limitations of the included studies. Nevertheless, BTX-A might be considered a viable treatment option for neuralgia.